Friends,

100% response rate. Not "some improvement." Not "trending positive." Every. Single. MG patient in the CAR-T trial responded. WOW, I had to triple verify that one. Let’s hope that all carries over to our community. I keep say these are game changers but the truth is we all hope there is a game ending. So be positive and see what the amazing people of medicine are doing for all of us.

Cell therapy isn't cancer-only anymore. The question patients are asking: "How do I know if I qualify?"

✅ CAR-T hits 100% response in MG—immune reset is real
✅ Cell therapy proven for NMOSD—beyond relapse control
✅ CIDP gets clearer diagnosis standards—faster trial access
✅ Top patient question answered—"Can I get into trials?"

⏱ Read time: 3 minutes

The headline: KYV-101 CAR-T therapy achieved 100% response rate in phase 2 myasthenia gravis trial. Patients off all other immune drugs by week 12.

The numbers that matter:

Why it matters: This isn't symptom management—it's immune system reset. Your body's B cells stop attacking nerve connections, potentially for years.

Texas connection: UT Southwestern, Houston Methodist, and Texas Children's preparing CAR-T infrastructure. Get established at major centers NOW for trial access later.

🎯 Action: Join MG Foundation trial notification list at myasthenia.org

Cell Therapy Hits NMOSD
Mesenchymal stem cells and CAR-T now in NMOSD trials. Early data: fewer relapses, better function in treatment-resistant cases. Could push beyond "relapse control" to true immune reprogramming. UT Southwestern and Houston Methodist run active NMOSD clinics.

CIDP Gets Clearer Definitions
International experts standardizing what counts as CIDP versus mimics. Result: faster correct diagnosis, better trial matching. Plus: VYVGART's ADHERE trial showed 67% improvement, 61% relapse reduction. Europe approved; North America education rolling out.

Trial Eligibility Reality Check
Most CAR-T studies want: ages 18-75, antibody-positive, treatment-resistant, functionally impaired. For CIDP: ongoing relapses despite IVIG/steroids. In stable remission? Probably not eligible yet.

"How do I know if I personally qualify for these trials?"

That's the #1 question in webinars, forums, and clinic visits right now.

What patients need to know:

Texas reality: Community neurologists often lack current trial info. Major center evaluation usually required for definitive answer.

🔗 Start here: GBS/CIDP Foundation: 1-866-224-3301

"I asked about CAR-T at every appointment for a year. My neurologist finally connected me with Houston Methodist's research coordinator. Six months post-treatment, I forget I have MG most days. The difference isn't just physical—it's getting your future back." — Houston MG patient, support group share

The pattern: Aggressive advocacy + major center relationships = trial access.

Houston Methodist Neuromuscular Center
Active trials, NMOSD specialty clinic, comprehensive CIDP diagnostics

UT Southwestern Neuromuscular Program
CAR-T infrastructure development, same-week acute appointments

Texas Children's Cell & Gene Therapy
10,000+ patients treated, proven complex therapy infrastructure

Key point: Establish care NOW for trial access when studies open.

CAR-T: Reprograms your immune cells to eliminate autoimmune attackers, then stops—a reset, not lifelong suppression

FcRn Blockers: New CIDP meds reducing harmful antibodies while preserving immune function (VYVGART/efgartigimod)

Refractory: Doesn't respond to standard treatments—main trial qualification

We're launching NeuroAIAlly—exploring how AI and adaptive technology are changing rare disease research and advocacy, with the same Texas warmth you expect from TNR.

Weekly deep-dives on AI diagnosis tools, using AI for treatment research, automation for advocacy work, and honest talk about what AI can (and can't) do for rare disease families. Written by real humans using adaptive tech daily. No hype, no Silicon Valley nonsense—just practical tools that work.

First issue soon | Subscribe a neuroaiAlly

We are not doctors—always check with your provider before making health decisions. Spotted an error or have input? Let us know! All personal stories are anonymous unless you say otherwise. Sponsors never influence our content. We strive for accuracy, but your feedback keeps us honest. When in doubt, talk to your doc—then come swap stories with us!

© 2025 Texas NeuroRare | Bi-Weekly Publication
📧 Contact: